AUG 04, 2022 10:01 AM PDT

Medical Marijuana Research Expansion Act

WRITTEN BY: Helaine Krysik

The U.S. House recently revised and passed an updated version of a cannabis research bill, which could significantly affect how the science community works with the plant. The Medical Marijuana Research Expansion Act, if approved by the Senate and the President, would be a quantum leap forward in terms of weed research.

The Act would jumpstart cannabis science research, as well as the related drug development, as one of the biggest changes would instituting deadlines in which regulatory agencies can approve scientists’ applications for clinical trials.

The legislation would also require that the U.S. Attorney General actively solicit applications from the science community for the research and trials. It would also stipulate that a timeline be instituted for the application process.

Licensed scientists would now have access to cannabis flower and other products that they have long been denied for research, as long as the flower and products are legally produced according to their respective state guidelines. This would be a considerable catalyst in weed science on the university level in legal cannabis states.

The bill, if passed, would also require agencies like the U.S. Department of Health & Human Services to report on the therapeutic benefits of CBD and THC in serious health conditions.

The FDA would be permitted to analyze CBD and medical THC containing products, and publish conclusions available to the public so that potential buyers can make more informed purchasing decisions.

The biggest takeaway from this pending legislation, if passed, is not only would it apply deadlines to approving agencies, but it would do more to raise the profile of cannabis research overall.

The Act would help ease and eventually eliminate the bias that has long been applied to studies in weed science. This lack of bias would help to further legitimize the plant’s image overall, and spawn all sorts of new business opportunities, many of which would be in areas that no one can yet predict.

 

Sources: Congress.gov, hhs.gov, MJBizDaily

About the Author
Marketing
Helaine is a cannabis industry writer and marketing consultant. She has been active in the Illinois cannabis industry since 2020, and writes for a variety of national publications.
You May Also Like
AUG 04, 2022
Cannabis Sciences
Don't Smoke the Reclaim. Here's Why.
AUG 04, 2022
Don't Smoke the Reclaim. Here's Why.
Here's what reclaim is, why you should leave it alone, and what you should do with it instead.
SEP 29, 2022
Cannabis Sciences
What are Cannabinoid Acids?
SEP 29, 2022
What are Cannabinoid Acids?
How does your favorite cannabis strain create its concentration of THC or CBD? Here's what cannabinoid acids are, and ho ...
OCT 26, 2022
Drug Discovery & Development
Study Suggests FDA Oversight of Vaping Makes Minimal Impact
OCT 26, 2022
Study Suggests FDA Oversight of Vaping Makes Minimal Impact
A recent study published in Tobacco Control suggested that current Food and Drug Administration (FDA) oversight of the A ...
NOV 17, 2022
Cannabis Sciences
Medical Cannabis Patients Feel Validated by Changes in Cannabis Stigma and Policy
NOV 17, 2022
Medical Cannabis Patients Feel Validated by Changes in Cannabis Stigma and Policy
Drexel University researchers examined the effects of California’s 2016 recreational cannabis use law among young ...
NOV 17, 2022
Cannabis Sciences
What It Means If You Are Ediblocked
NOV 17, 2022
What It Means If You Are Ediblocked
What ediblocking is, and how it affects you
NOV 18, 2022
Plants & Animals
Cannabis Users Have Worse Bypass Outcomes, Increased Risk of Amputation
NOV 18, 2022
Cannabis Users Have Worse Bypass Outcomes, Increased Risk of Amputation
Lower extremity bypass surgery is a common procedure used to address occluded arteries in the leg, usually with the goal ...
Loading Comments...